Schrodinger, Inc. (SDGR) Form 8-K — Nov 4, 2026
Schrodinger reported Q3 2026 results with ACV of $44.7 million, up 17%, and total revenue of $64.5 million, up 19%, driven by $24.2 million of drug discovery revenue that included a milestone payment from Structure Therapeutics. The company raised full-year 2026 guidance, lifting ACV to $222-232 million (from $218-228 million) and drug discovery revenue to $75-85 million (from $65-75 million). Net loss widened to $37.7 million from $32.8 million, though adjusted EBITDA improved to -$16.8 million from -$33.6 million, and the company held $373 million in cash and securities.
Key figures
- Revenue
- 64491000
- Guidance
- FY2026 ACV of $222M-$232M (12-17% growth, raised from $218M-$228M); drug discovery revenue $75M-$85M (raised from $65M-$75M); operating expenses expected below 2025.
- Revenue Yoy
- 19%
- Cash Position
- 373000000
- Acv q3
- $44.7M (+17%)
- Adjusted ebitda q3
- -$16.8M (vs -$33.6M prior year)
- Software revenue q3
- $38.2M (+6%)
- Operating expenses q3
- $64.4M (-13%)
- Software gross margin
- 75%
- Operating cash flow 9mo
- -$96.5M (vs +$30.0M prior year)
- Drug discovery revenue q3
- $24.2M (vs $13.0M prior year)
- Acv ex contribution growth
- 24%
- Hosted software revenue q3
- $17.2M (+49%)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.